Self-Amplifying mRNA Vaccines Market

Global Self-Amplifying mRNA Vaccines Market Size, Trends & Analysis - Forecasts to 2029 By Target Disease (COVID-19, Influenza, Cancer (e.g., Melanoma, Breast Cancer), and Other Infectious Diseases), By Development Phase (Preclinical, Clinical (Phase I, II, III), and Commercialized), and By Region (North America, Asia Pacific, Central & South America, Europe, and Middle East and Africa), Competitive Landscape, Company Market Share Analysis, and End User Analysis

Category Healthcare
Format
  • ms word
  • ms excel
  • ms ppt
  • pdf
This report was recently updated on June 8 2024 with the latest and most recent market numbers

Global Self-Amplifying mRNA Vaccines Market Size

The global self-amplifying mRNA vaccines (SMA) market is analyzed to grow at a CAGR of 2.7% during the forecast period from 2024 to 2029. Self-amplifying mRNA vaccines employ a new approach by delivering mRNA molecules to cells, stimulating them to create antigens. This prompts an immune response against particular pathogens like viruses. Unlike standard vaccines, self-amplifying mRNA vaccines aim to enhance antigen production in the body, potentially resulting in a stronger and longer-lasting immune reaction.

The market is driven by factors such as preparedness for epidemics and the potential for having enhanced immune systems in the body. The COVID-19 pandemic has highlighted the urgent need for innovative vaccine technologies that rapidly respond to emerging infectious diseases. Self-amplifying mRNA vaccines offer a promising solution due to their ability to be quickly designed and manufactured, thus driving investment and research in this field. Self-amplifying mRNA vaccines have shown promise in preclinical and early clinical studies for eliciting robust and durable immune responses. This potential for enhanced immunogenicity compared to traditional vaccines is a significant driver for developing and adopting self-amplifying mRNA vaccines. Self-amplifying mRNA vaccines offer personalized vaccine development, aligning with the trend toward precision medicine. This creates opportunities for targeted vaccine therapies tailored to individual genetic profiles or specific disease antigens.

One of the primary challenges self-amplifying mRNA vaccines market faces is the complexity and scalability of manufacturing processes. These vaccines require specialized production facilities and techniques, which may limit their widespread adoption and accessibility, especially in resource-limited settings.

global self-amplifying mrna vaccines market

Global Self-Amplifying mRNA Vaccines Market: By Target Disease

Based on target disease, the market is segmented into COVID-19, influenza, cancer (e.g., melanoma, breast cancer), and other infectious diseases. The COVID-19 segment is expected to hold the largest share of the market during the forecast period. This dominance stems from the urgent global need for effective vaccines against the virus. With ongoing vaccination campaigns and the continuous threat of COVID-19 variants, the demand for self-amplifying mRNA vaccines targeting this disease is expected to remain high, contributing significantly to the market share.

The cancer segment is projected to grow fastest during the forecast period. The cancer segment is poised for rapid growth in the forecast period due to increasing research and advancements in cancer immunotherapy. Self-amplifying mRNA vaccines offer promising avenues for personalized cancer treatment, targeting specific antigens associated with various cancer types like melanoma and breast cancer. This, coupled with the rising prevalence of cancer and the demand for more effective therapies, drives the projected fastest growth in this segment.

Global Self-Amplifying mRNA Vaccines Market: By Development Phase

Based on development phase, the market is segmented into preclinical, clinical (Phase I, II, III), and commercialized. The commercial segment is expected to hold the largest share of the market during the forecast period. The commercial segment's dominance is due to the existence of approved vaccines for urgent public health needs such as COVID-19. These vaccines have undergone rigorous testing and regulatory approval, enabling their widespread distribution and use, thereby contributing significantly to the segment's market share.

The clinical (Phase I, II, III) segment is projected to grow fastest during the forecast period. This is driven by ongoing research and development efforts, with numerous vaccine candidates advancing through clinical trials toward potential commercialization. As more candidates progress through the clinical phases, the clinical segment is expected to expand rapidly, reflecting the increasing pipeline of self-amplifying mRNA vaccines in development.

asia pacific self-amplifying mrna vaccines market

Global Self-Amplifying mRNA Vaccines Market: By Region

North America is analyzed to be the largest region in the global self-amplifying mRNA vaccines market during the forecast period. The region's market growth is attributed to its robust research infrastructure, significant investments in vaccine development, and strong regulatory frameworks, all of which foster innovation and drive market growth.

Asia Pacific is analyzed to be the fastest-growing region in the global self-amplifying mRNA vaccines market during the forecast period. Rising healthcare spending in Asia Pacific is fueling increased investment in vaccine research and development. The expansion of the pharmaceutical sector in the region is driving significant funding toward innovative vaccine technologies. Moreover, the high population density in Asia Pacific creates a strong demand for effective vaccines to combat infectious diseases. Additionally, outbreaks of infectious diseases prompt heightened investment in novel vaccine platforms such as self-amplifying mRNA.

Global Self-Amplifying mRNA Vaccines Market Share and Competitor Analysis

Pfizer-BioNTech and Moderna, Inc., Arcturus Therapeutics, Gennova Biopharmaceuticals Ltd, Creative BioLabs, CureVac AG and GSK, Ziphius Vaccines, HDT Bio Corp, Acuitas Therapeutics, Inc., GenScript Biotech Corporation, Nature's Toolbox, Inc. (NTx), RNAimmune, AstraZeneca and VaxEquity, and Chimeron Bio, among others, are some of the key players operating in the global market.

Please note: This is not an exhaustive list of companies profiled in the report.

Global Self-Amplifying mRNA Vaccines Market: Recent Developments

In August 2023, CureVac announced the dosing of the first participant in the phase 2 study of modified COVID-19 mRNA vaccine candidates developed in collaboration with GSK. The first data read-out of the study is expected to be early in the first half of 2024.

1          STRATEGIC INSIGHTS ON NEW REVENUE POCKETS

1.1       Strategic Opportunity & Attractiveness Analysis

1.1.1   Hot Revenue Pockets

1.1.2   Market Attractiveness Score

1.1.3   Revenue Impacting Opportunity

1.1.4   High Growing Region/Country

1.1.5   Competitor Analysis

1.1.6   Consumer Analysis

1.2       Global Market Estimates' View

1.3       Strategic Insights across Business Functions

1.3.1   For Chief Executive Officers

1.3.2   For Chief Marketing Officers

1.3.3   For Chief Strategy Officers

1.4       Evaluate the Potential of your Existing Business Lines vs. New Lines to Enter Into

2          TECHNOLOGICAL TRENDS

2.1       Technological Adoption Rate

2.2       Current Trend Impact Analysis

2.3       Future Trend Impact Analysis

3          GLOBAL MARKET OUTLOOK

3.1       Market Pyramid Analysis

3.1.1   Introduction

3.1.2   Adjacent Market Opportunities

3.1.3   Ancillary Market Opportunities

3.2       Demand Side Analysis

3.2.1   Market Drivers: Impact Analysis

3.2.2   Market Restraints: Impact Analysis

3.2.3   Market Opportunities: Impact Analysis

3.2.4   Market Challenges: Impact Analysis

3.3       Supply Side Analysis

3.3.1   Porter’s Five Forces Analysis

3.3.1.1            Threat of New Entrants

3.3.1.2            Threat of New Substitutes

3.3.1.3            Bargaining Power of Suppliers

3.3.1.4            Bargaining Power of Buyers

3.3.1.5            Intensity of Competitive Rivalry

3.3.2   SWOT Analysis; By Factor (Political & Legal, Economic, and Technological)

3.3.2.1            Political Landscape

3.3.2.2            Economic Landscape

3.3.2.3            Social Landscape

3.3.2.4            Technology Landscape

3.3.3   Value Chain Analysis

3.3.4   Trend Analysis

3.3.5   Gap Analysis

3.3.6   Cost Analysis

4          GLOBAL SELF-AMPLIFYING MRNA VACCINES MARKET, BY TARGET DISEASE

4.1       Introduction

4.2       Self-Amplifying mRNA Vaccines Market: Target Disease Scope Key Takeaways

4.3       Revenue Growth Analysis, 2023 & 2029

4.4       COVID-19

4.4.1   COVID-19 Market Estimates and Forecast, 2021-2029 (USD Million)

4.5       Cancer (e.g., Melanoma, Breast Cancer)

4.5.1   Cancer (e.g., Melanoma, Breast Cancer) Market Estimates and Forecast, 2021-2029 (USD Million)

4.6       Other Infectious Diseases

4.6.1   Other Infectious Diseases Market Estimates and Forecast, 2021-2029 (USD Million)

5          GLOBAL SELF-AMPLIFYING MRNA VACCINES MARKET, BY DEVELOPMENT PHASE

5.1       Introduction

5.2       Self-Amplifying mRNA Vaccines Market: Development Phase Scope Key Takeaways

5.3       Revenue Growth Analysis, 2023 & 2029

5.4       Preclinical

5.4.1   Preclinical Market Estimates and Forecast, 2021-2029 (USD Million)

5.5       Clinical (Phase I, II, III)

5.5.1   Clinical (Phase I, II, III) Market Estimates and Forecast, 2021-2029 (USD Million)

5.6       Commercialized

5.6.1   Commercialized Market Estimates and Forecast, 2021-2029 (USD Million)

6          GLOBAL SELF-AMPLIFYING MRNA VACCINES MARKET, BY REGION

6.1       Introduction

6.2       North America Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)

6.2.1   By Target Disease

6.2.2   By Development Phase

6.2.3   By Country

6.2.3.1            U.S. Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)

6.2.3.1.1         By Target Disease

6.2.3.1.2         By Development Phase

6.2.3.2            Canada Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)

6.2.3.2.1         By Target Disease

6.2.3.2.2         By Development Phase

6.2.3.3            Mexico Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)

6.2.3.3.1         By Target Disease

6.2.3.3.2         By Development Phase

6.3       Europe Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)

6.3.1   By Target Disease

6.3.2   By Development Phase

6.3.3   By Country

6.3.3.1            Germany Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)

6.3.3.1.1         By Target Disease

6.3.3.1.2         By Development Phase

6.3.3.2            U.K. Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)

6.3.3.2.1         By Target Disease

6.3.3.2.2         By Development Phase

6.3.3.3            France Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)

6.3.3.3.1         By Target Disease

6.3.3.3.2         By Development Phase

6.3.3.4            Italy Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)

6.3.3.4.1         By Target Disease

6.3.3.4.2         By Development Phase

6.3.3.5            Spain Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)

6.3.3.5.1         By Target Disease

6.3.3.5.2         By Development Phase

6.3.3.6            Netherlands Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)

6.3.3.6.1         By Target Disease

6.3.3.6.2         By Development Phase

6.3.3.7            Rest of Europe Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)

6.3.3.6.1         By Target Disease

6.3.3.6.2         By Development Phase

6.4       Asia Pacific Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)

6.4.1   By Target Disease

6.4.2   By Development Phase

6.4.3   By Country

6.4.3.1            China Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)

6.4.3.1.1         By Target Disease

6.4.3.1.2         By Development Phase

6.4.3.2            Japan Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)

6.4.3.2.1         By Target Disease

6.4.3.2.2         By Development Phase

6.4.3.3            India Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)

6.4.3.3.1         By Target Disease

6.4.3.3.2         By Development Phase

6.4.3.4            South Korea Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)

6.4.3.4.1         By Target Disease

6.4.3.4.2         By Development Phase

6.4.3.5            Singapore Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)

6.4.3.5.1         By Target Disease

6.4.3.5.2         By Development Phase

6.4.3.6            Malaysia Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)

6.4.3.6.1         By Target Disease

6.4.3.6.2         By Development Phase

6.4.3.7            Thailand Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)

6.4.3.6.1         By Target Disease

6.4.3.6.2         By Development Phase

6.4.3.8            Indonesia Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)

6.4.3.7.1         By Target Disease

6.4.3.7.2         By Development Phase

6.4.3.9            Vietnam Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)

6.4.3.8.1         By Target Disease

6.4.3.8.2         By Development Phase

6.4.3.10          Taiwan Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)

6.4.3.10.1 By Target Disease

6.4.3.10.2 By Development Phase

6.4.3.11          Rest of Asia Pacific Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)

6.4.3.11.1 By Target Disease

6.4.3.11.2 By Development Phase

6.5       Middle East and Africa Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)

6.5.1   By Target Disease

6.5.2   By Development Phase

6.5.3   By Country

6.5.3.1            Saudi Arabia Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)

6.5.3.1.1         By Target Disease

6.5.3.1.2         By Development Phase

6.5.3.2            U.A.E. Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)

6.5.3.2.1         By Target Disease

6.5.3.2.2         By Development Phase

6.5.3.3            Israel Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)

6.5.3.3.1         By Target Disease

6.5.3.3.2         By Development Phase

6.5.3.4            South Africa Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)

6.5.3.4.1         By Target Disease

6.5.3.4.2         By Development Phase

6.5.3.5            Rest of Middle East and Africa Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)

6.5.3.5.1         By Target Disease

6.5.3.5.2         By Development Phase

6.6       Central & South America Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)

6.6.1   By Target Disease

6.6.2   By Development Phase

6.6.3   By Country

6.6.3.1            Brazil Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)

6.6.3.1.1         By Target Disease

6.6.3.1.2         By Development Phase

6.6.3.2            Argentina Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)

6.6.3.2.1         By Target Disease

6.6.3.2.2         By Development Phase

6.6.3.3            Chile Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)

6.6.3.3.1         By Target Disease

6.6.3.3.2         By Development Phase

6.6.3.3            Rest of Central & South America Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)

6.6.3.3.1         By Target Disease

6.6.3.3.2         By Development Phase

7          COMPETITIVE LANDCAPE

7.1       Company Market Share Analysis

7.2       Four Quadrant Positioning Matrix

7.2.1   Market Leaders

7.2.2   Market Visionaries

7.2.3   Market Challengers

7.2.4   Niche Market Players

7.3       Vendor Landscape

7.3.1   North America

7.3.2   Europe

7.3.3   Asia Pacific

7.3.4   Rest of the World

7.4       Company Profiles  

7.4.1   Pfizer-BioNTech and Moderna, Inc.

7.4.1.1            Business Description & Financial Analysis

7.4.1.2            SWOT Analysis

7.4.1.3            Products & Services Offered

7.4.1.4            Strategic Alliances between Business Partners

7.4.2   Arcturus Therapeutics

7.4.2.1            Business Description & Financial Analysis

7.4.2.2            SWOT Analysis

7.4.2.3            Products & Services Offered

7.4.2.4            Strategic Alliances between Business Partners

7.4.3   Gennova Biopharmaceuticals Ltd

7.4.3.1            Business Description & Financial Analysis

7.4.3.2            SWOT Analysis

7.4.3.3            Products & Services Offered

7.4.3.4            Strategic Alliances between Business Partners

7.4.4   Creative BioLabs

7.4.4.1            Business Description & Financial Analysis

7.4.4.2            SWOT Analysis

7.4.4.3            Products & Services Offered

7.4.4.4            Strategic Alliances between Business Partners

7.4.5   CureVac AG and GSK

7.4.5.1            Business Description & Financial Analysis

7.4.5.2            SWOT Analysis

7.4.5.3            Products & Services Offered

7.4.5.4            Strategic Alliances between Business Partners

7.4.6   ZIPHIUS VACCINES

7.4.6.1            Business Description & Financial Analysis

7.4.6.2            SWOT Analysis

7.4.6.3            Products & Services Offered

7.4.6.4            Strategic Alliances between Business Partners

7.4.7   HDT Bio Corp  

7.4.7.1            Business Description & Financial Analysis

7.4.7.2            SWOT Analysis

7.4.7.3            Products & Services Offered

7.4.7.4            Strategic Alliances between Business Partners

7.4.8   Acuitas Therapeutics, Inc.

7.4.8.1            Business Description & Financial Analysis

7.4.8.2            SWOT Analysis

7.4.8.3            Products & Services Offered

7.4.8.4            Strategic Alliances between Business Partners

7.4.9   GenScript Biotech Corporation

7.4.9.1            Business Description & Financial Analysis

7.4.9.2            SWOT Analysis

7.4.9.3            Products & Services Offered

7.4.9.4            Strategic Alliances between Business Partners

7.4.10 Nature’s Toolbox, Inc. (NTx)

7.4.10.1 Business Description & Financial Analysis

7.4.10.2 SWOT Analysis

7.4.10.3 Products & Services Offered

7.4.10.4 Strategic Alliances between Business Partners

7.4.11 RNAimmune  

7.4.11.1 Business Description & Financial Analysis

7.4.11.2 SWOT Analysis

7.4.11.3 Products & Services Offered

7.4.11.4 Strategic Alliances between Business Partners

7.4.12 AstraZeneca and VaxEquity  

7.4.12.1 Business Description & Financial Analysis

7.4.12.2 SWOT Analysis

7.4.12.3 Products & Services Offered

7.4.12.4 Strategic Alliances between Business Partners

7.4.13 Chimeron Bio  

7.4.13.1 Business Description & Financial Analysis

7.4.13.2 SWOT Analysis

7.4.13.3 Products & Services Offered

7.4.13.4 Strategic Alliances between Business Partners

7.4.14 Other Companies

7.4.14.1 Business Description & Financial Analysis

7.4.14.2 SWOT Analysis

7.4.14.3 Products & Services Offered

7.4.14.4 Strategic Alliances between Business Partners

8          RESEARCH METHODOLOGY

8.1       Market Introduction

8.1.1   Market Definition

8.1.2   Market Scope & Segmentation

8.2       Information Procurement

8.2.1   Secondary Research

8.2.1.1            Purchased Databases

8.2.1.2            GMEs Internal Data Repository

8.2.1.3            Secondary Resources & Third Party Perspectives

8.2.1.4            Company Information Sources

8.2.2   Primary Research

8.2.2.1            Various Types of Respondents for Primary Interviews

8.2.2.2            Number of Interviews Conducted throughout the Research Process

8.2.2.3            Primary Stakeholders

8.2.2.4            Discussion Guide for Primary Participants

8.2.3   Expert Panels

8.2.3.1            Expert Panels Across 30+ Industry

8.2.4   Paid Local Experts

8.2.4.1            Paid Local Experts Across 30+ Industry Across each Region

8.3       Market Estimation

8.3.1   Top-Down Approach

8.3.1.1            Macro-Economic Indicators Considered

8.3.1.2            Micro-Economic Indicators Considered

8.3.2   Bottom Up Approach

8.3.2.1            Company Share Analysis Approach

8.3.2.2            Estimation of Potential Product Sales

8.4       Data Triangulation

8.4.1   Data Collection

8.4.2   Time Series, Cross Sectional & Panel Data Analysis

8.4.3   Cluster Analysis

8.5       Analysis and Output

8.5.1   Inhouse AI Based Real Time Analytics Tool

8.5.2   Output From Desk & Primary Research

8.6       Research Assumptions & Limitations

8.6.1   Research Assumptions

8.6.2   Research Limitations

LIST OF TABLES

1 Global Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)

2 COVID-19 Market, By Region, 2021-2029 (USD Mllion)           

3 Cancer (e.g., Melanoma, Breast Cancer) Market, By Region, 2021-2029 (USD Mllion)

4 Other Infectious Diseases Market, By Region, 2021-2029 (USD Mllion)    

5 Global Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)

6 Preclinical Market, By Region, 2021-2029 (USD Mllion)     

7 Clinical (Phase I, II, III) Market, By Region, 2021-2029 (USD Mllion)

8 Commercialized Market, By Region, 2021-2029 (USD Mllion)          

9 Regional Analysis, 2021-2029 (USD Mllion)

10 North America Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)       

11 North America Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)      

12 North America Self-Amplifying mRNA Vaccines Market, By Country, 2021-2029 (USD Mllion)    

13 U.S. Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)

14 U.S. Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)    

15 Canada Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)

16 Canada Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)

17 Mexico Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)

18 Mexico Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)

19 Europe Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)

20 Europe Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)

21 Europe Self-Amplifying mRNA Vaccines Market, By Country, 2021-2029 (USD Mllion)

22 Germany Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)  

23 Germany Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)

24 U.K. Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)

25 U.K. Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)    

26 France Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)

27 France Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)

28 Italy Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)

29 Italy Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)  

30 Spain Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)

31 Spain Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)

32 Netherlands Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)       

33 Netherlands Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)

34 Rest Of Europe Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)       

35 Rest Of Europe Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)      

36 Asia Pacific Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)       

37 Asia Pacific Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)

38 Asia Pacific Self-Amplifying mRNA Vaccines Market, By Country, 2021-2029 (USD Mllion)

39 China Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)

40 China Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)

41 Japan Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)

42 Japan Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)

43 India Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)

44 India Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)

45 South Korea Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)       

46 South Korea Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)

47 Singapore Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)

48 Singapore Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)

49 Thailand Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)   

50 Thailand Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)

51 Malaysia Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)  

52 Malaysia Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)

53 Indonesia Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)

54 Indonesia Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)

55 Vietnam Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)

56 Vietnam Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)

57 Taiwan Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)

58 Taiwan Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)

59 Rest of APAC Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)       

60 Rest of APAC Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)      

61 Middle East and Africa Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)      

62 Middle East and Africa Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)           

63 Middle East and Africa Self-Amplifying mRNA Vaccines Market, By country, 2021-2029 (USD Mllion)       

64 Saudi Arabia Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)       

65 Saudi Arabia Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)

66 UAE Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)

67 UAE Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)    

68 Israel Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)

69 Israel Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)

70 South Africa Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)       

71 South Africa Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)

72 Rest Of Middle East and Africa Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)

73 Rest Of Middle East and Africa Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)   

74 Central & South America Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)      

75 Central & South America Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)           

76 Central & South America Self-Amplifying mRNA Vaccines Market, By Country, 2021-2029 (USD Mllion)      

77 Brazil Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)

78 Brazil Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)

79 Chile Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)

80 Chile Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)

81 Argentina Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)

82 Argentina Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)

83 Rest Of Central & South America Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)

84 Rest Of Central & South America Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)   

85 Pfizer-BioNTech and Moderna, Inc.: Products & Services Offering           

86 Arcturus Therapeutics: Products & Services Offering    

87 Gennova Biopharmaceuticals Ltd: Products & Services Offering              

88 Creative BioLabs: Products & Services Offering   

89 CureVac AG and GSK: Products & Services Offering            

90 ZIPHIUS VACCINES: Products & Services Offering    

91 HDT Bio Corp : Products & Services Offering           

92 Acuitas Therapeutics, Inc.: Products & Services Offering              

93 GenScript Biotech Corporation: Products & Services Offering  

94 Nature’s Toolbox, Inc. (NTx): Products & Services Offering            

95 RNAimmune: Products & Services Offering               

96 AstraZeneca and VaxEquity: Products & Services Offering            

97 Chimeron Bio: Products & Services Offering          

98 Other Companies: Products & Services Offering  

LIST OF FIGURES

1 Global Self-Amplifying mRNA Vaccines Market Overview

2 Global Self-Amplifying mRNA Vaccines Market Value From 2021-2029 (USD Mllion)

3 Global Self-Amplifying mRNA Vaccines Market Share, By Target Disease (2023)

4 Global Self-Amplifying mRNA Vaccines Market Share, By Development Phase (2023)

5 Global Self-Amplifying mRNA Vaccines Market, By Region (Asia Pacific Market)

6 Technological Trends In Global Self-Amplifying mRNA Vaccines Market

7 Four Quadrant Competitor Positioning Matrix

8 Impact Of Macro & Micro Indicators On The Market

9 Impact Of Key Drivers On The Global Self-Amplifying mRNA Vaccines Market

10 Impact Of Challenges On The Global Self-Amplifying mRNA Vaccines Market

11 Porter’s Five Forces Analysis

12 Global Self-Amplifying mRNA Vaccines Market: By Target Disease Scope Key Takeaways

13 Global Self-Amplifying mRNA Vaccines Market, By Target Disease Segment: Revenue Growth Analysis

14 COVID-19 Market, By Region, 2021-2029 (USD Mllion)         

15 Cancer (e.g., Melanoma, Breast Cancer) Market, By Region, 2021-2029 (USD Mllion)

16 Other Infectious Diseases Market, By Region, 2021-2029 (USD Mllion)

17 Global Self-Amplifying mRNA Vaccines Market: By Development Phase Scope Key Takeaways

18 Global Self-Amplifying mRNA Vaccines Market, By Development Phase Segment: Revenue Growth Analysis

19 Preclinical Market, By Region, 2021-2029 (USD Mllion)         

20 Clinical (Phase I, II, III) Market, By Region, 2021-2029 (USD Mllion)

21 Commercialized Market, By Region, 2021-2029 (USD Mllion)

22 Regional Segment: Revenue Growth Analysis

23 Global Self-Amplifying mRNA Vaccines Market: Regional Analysis

24 North America Self-Amplifying mRNA Vaccines Market Overview

25 North America Self-Amplifying mRNA Vaccines Market, By Target Disease

26 North America Self-Amplifying mRNA Vaccines Market, By Development Phase

27 North America Self-Amplifying mRNA Vaccines Market, By Country

28 U.S. Self-Amplifying mRNA Vaccines Market, By Target Disease

29 U.S. Self-Amplifying mRNA Vaccines Market, By Development Phase

30 Canada Self-Amplifying mRNA Vaccines Market, By Target Disease

31 Canada Self-Amplifying mRNA Vaccines Market, By Development Phase

32 Mexico Self-Amplifying mRNA Vaccines Market, By Target Disease

33 Mexico Self-Amplifying mRNA Vaccines Market, By Development Phase

34 Four Quadrant Positioning Matrix

35 Company Market Share Analysis

36 Pfizer-BioNTech and Moderna, Inc.: Company Snapshot

37 Pfizer-BioNTech and Moderna, Inc.: SWOT Analysis

38 Pfizer-BioNTech and Moderna, Inc.: Geographic Presence

39 Arcturus Therapeutics: Company Snapshot

40 Arcturus Therapeutics: SWOT Analysis

41 Arcturus Therapeutics: Geographic Presence

42 Gennova Biopharmaceuticals Ltd: Company Snapshot

43 Gennova Biopharmaceuticals Ltd: SWOT Analysis

44 Gennova Biopharmaceuticals Ltd: Geographic Presence

45 Creative BioLabs: Company Snapshot

46 Creative BioLabs: Swot Analysis

47 Creative BioLabs: Geographic Presence

48 CureVac AG and GSK: Company Snapshot

49 CureVac AG and GSK: SWOT Analysis

50 CureVac AG and GSK: Geographic Presence

51 ZIPHIUS VACCINES: Company Snapshot

52 ZIPHIUS VACCINES: SWOT Analysis

53 ZIPHIUS VACCINES: Geographic Presence

54 HDT Bio Corp : Company Snapshot

55 HDT Bio Corp : SWOT Analysis

56 HDT Bio Corp : Geographic Presence

57 Acuitas Therapeutics, Inc.: Company Snapshot

58 Acuitas Therapeutics, Inc.: SWOT Analysis

59 Acuitas Therapeutics, Inc.: Geographic Presence

60 GenScript Biotech Corporation.: Company Snapshot

61 GenScript Biotech Corporation.: SWOT Analysis

62 GenScript Biotech Corporation.: Geographic Presence

63 Nature’s Toolbox, Inc. (NTx): Company Snapshot

64 Nature’s Toolbox, Inc. (NTx): SWOT Analysis

65 Nature’s Toolbox, Inc. (NTx): Geographic Presence

66 RNAimmune: Company Snapshot

67 RNAimmune: SWOT Analysis

68 RNAimmune: Geographic Presence

69 AstraZeneca and VaxEquity: Company Snapshot

70 AstraZeneca and VaxEquity: SWOT Analysis

71 AstraZeneca and VaxEquity: Geographic Presence

72 Chimeron Bio: Company Snapshot

73 Chimeron Bio: SWOT Analysis

74 Chimeron Bio: Geographic Presence

75 Other Companies: Company Snapshot

76 Other Companies: SWOT Analysis

77 Other Companies: Geographic Presence

The Global Self-Amplifying mRNA Vaccines Market has been studied from the year 2019 till 2029. However, the CAGR provided in the report is from the year 2024 to 2029. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.

Self-Amplifying mRNA Vaccines Market Size

The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Self-Amplifying mRNA Vaccines Market.

Self-Amplifying mRNA Vaccines Market Growth

The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.

Self-Amplifying mRNA Vaccines Market Trends

Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.

Self-Amplifying mRNA Vaccines Market Share

We value your investment and offer free customization with every report to fulfil your exact research needs.
This website is secure and your personal details are safe. Privacy
You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The global self-amplifying mRNA vaccines (SMA) market is analyzed to grow at a CAGR of 2.7% during the forecast period from 2024 to 2029.
The key players operating in the market are Pfizer-BioNTech and Moderna, Inc., Arcturus Therapeutics, Gennova Biopharmaceuticals Ltd, Creative BioLabs, CureVac AG and GSK, Ziphius Vaccines, HDT Bio Corp, Acuitas Therapeutics, Inc., GenScript Biotech Corporation, Natures Toolbox, Inc. (NTx), RNAimmune, AstraZeneca and VaxEquity, and Chimeron Bio, among others.
Self-amplifying mRNA vaccines offer personalized vaccine development, aligning with the trend toward precision medicine. This creates opportunities for targeted vaccine therapies tailored to individual genetic profiles or specific disease antigens.
Global self-amplifying mRNA vaccines market growth is driven by preparedness for epidemics and potential for developing enhanced immune systems.

Tailor made solutions just for you

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

OUR CLIENTS

  • Client of Global Market Estimates - Fedex
  • Client of Global Market Estimates - Samsung
  • Client of Global Market Estimates - Siemens
  • Client of Global Market Estimates - Lonza
  • Client of Global Market Estimates - DuPont
  • Client of Global Market Estimates - Medtronic
  • Client of Global Market Estimates - Toray
  • Client of Global Market Estimates - Signify
  • Client of Global Market Estimates - Teledyne
  • Client of Global Market Estimates - Trelleborg
  • Client of Global Market Estimates - Kikkoman Biochemifa
  • Client of Global Market Estimates - Leoni
  • Client of Global Market Estimates - Molnlycke
  • Client of Global Market Estimates - Spirent
  • Client of Global Market Estimates - Tokyo Electron Limited
  • Client of Global Market Estimates - Aranca
  • Client of Global Market Estimates - Asahi Kasei
  • Client of Global Market Estimates - Chimai
  • Client of Global Market Estimates - Grapsud
  • Client of Global Market Estimates - Horiba
  • Client of Global Market Estimates - Indorama
  • Client of Global Market Estimates - L&T
  • Client of Global Market Estimates - Integralife
  • Client of Global Market Estimates - Synamedia
  • Client of Global Market Estimates - Sorrento Therapeutics
  • Client of Global Market Estimates - Solenis
  • Client of Global Market Estimates - Sartorius